ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferrigno, D
Right arrow Articles by Biggi, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferrigno, D
Right arrow Articles by Biggi, A
Eur Respir J 1994; 7: 186-197
Copyright © ERS Journals Ltd 1994

Original Articles

Serum tumour markers in lung cancer: history, biology and clinical applications

D Ferrigno, G Buccheri, and A Biggi

The association of biological markers with cancer has been recognized for many decades. Current interest in markers for cancer arose in the mid 1960s, with the discoveries of alpha-fetoprotein and carcinoembryonic antigen. They were called oncofetal proteins, because of their presence in high concentrations during embryonic development, their virtual disappearance in the neonatal period, and their reappearance with cancers of specific cell types. Essentially, any molecular species may be produced in abnormal amounts or under abnormal circumstances by a tumour, and thereby become useful as a tumour marker. Several tumour markers have been studied in lung cancer. Unfortunately, none of these appear to be sufficiently sensitive and specific to be reliable for screening and diagnostic purposes. However, there is a body of evidence which proves that at least some of these substances may be useful in the evaluation of the course and prognosis of the disease. This review presents data concerning the most studied and interesting tumour markers in lung cancer.


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
L. Zhong, G. E. Hidalgo, A. J. Stromberg, N. H. Khattar, J. R. Jett, and E. A. Hirschowitz
Using Protein Microarray as a Diagnostic Assay for Non-Small Cell Lung Cancer
Am. J. Respir. Crit. Care Med., November 15, 2005; 172(10): 1308 - 1314.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
Y. Sakao, S. Tomimitsu, Y. Takeda, M. Natsuaki, and T. Itoh
Carcinoembryonic antigen as a predictive factor for postoperative tumor relapse in early-stage lung adenocarcinoma
Eur. J. Cardiothorac. Surg., April 1, 2004; 25(4): 520 - 522.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
G. Buccheri and D. Ferrigno
Identifying patients at risk of early postoperative recurrence of lung cancer: a new use of the old CEA test
Ann. Thorac. Surg., March 1, 2003; 75(3): 973 - 980.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
G. Buccheri and D. Ferrigno
Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: A study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer
J. Thorac. Cardiovasc. Surg., November 1, 2001; 122(5): 891 - 899.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
D. Ferrigno, G. Buccheri, and I. Ricca
Prognostic significance of blood coagulation tests in lung cancer
Eur. Respir. J., April 1, 2001; 17(4): 667 - 673.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the European Respiratory Society.